In this Issue:
Receptor status changes in breast cancer
Ramucirumab extends survival in advanced gastric cancer
Second-line docetaxel in oesophagogastric adenocarcinoma
MRI-involved CRM predicts OS, DFS, and LR
mrEMVI: imaging biomarker in rectal cancer
Aflibercept + FOLFIRI: benefits across patient subgroups
Synchronous pulmonary metastases in CRC
Zoledronic acid vs ibandronate in bone metastases
No cardiac toxicity with raltitrexed
Improved survival in rectal cancer over time
Please login below to download this issue (PDF)